AU697847B2 - Method for the treatment or prevention of eczema/dermatitis - Google Patents
Method for the treatment or prevention of eczema/dermatitis Download PDFInfo
- Publication number
- AU697847B2 AU697847B2 AU77350/94A AU7735094A AU697847B2 AU 697847 B2 AU697847 B2 AU 697847B2 AU 77350/94 A AU77350/94 A AU 77350/94A AU 7735094 A AU7735094 A AU 7735094A AU 697847 B2 AU697847 B2 AU 697847B2
- Authority
- AU
- Australia
- Prior art keywords
- thr
- tyr
- document
- ser
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000004624 Dermatitis Diseases 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 16
- 208000010668 atopic eczema Diseases 0.000 title description 26
- 230000002265 prevention Effects 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 37
- 108010071384 Peptide T Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 9
- AKWRNBWMGFUAMF-ZESMOPTKSA-N (2s)-n-[(2s)-1-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amin Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(N)=O)CC1=CC=C(O)C=C1 AKWRNBWMGFUAMF-ZESMOPTKSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- IWHCAJPPWOMXNW-LYKMMFCUSA-N peptide t Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-LYKMMFCUSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101001017896 Homo sapiens U6 snRNA-associated Sm-like protein LSm1 Proteins 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 102100033314 U6 snRNA-associated Sm-like protein LSm1 Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 description 20
- 230000004054 inflammatory process Effects 0.000 description 20
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- 239000007921 spray Substances 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 3
- 108010069514 Cyclic Peptides Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229940057961 dermal spray Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- RMVRSNDYEFQCLF-UHFFFAOYSA-N phenyl mercaptan Natural products SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- -1 alkyl amide Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical class CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035901 vesication Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU77350/94A AU697847B2 (en) | 1993-09-24 | 1994-09-26 | Method for the treatment or prevention of eczema/dermatitis |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPM144993 | 1993-09-24 | ||
| AUPM1449 | 1993-09-24 | ||
| PCT/AU1994/000574 WO1995008338A1 (en) | 1993-09-24 | 1994-09-26 | Method for the treatment or prevention of eczema/dermatitis |
| AU77350/94A AU697847B2 (en) | 1993-09-24 | 1994-09-26 | Method for the treatment or prevention of eczema/dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7735094A AU7735094A (en) | 1995-04-10 |
| AU697847B2 true AU697847B2 (en) | 1998-10-15 |
Family
ID=3777229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU77350/94A Ceased AU697847B2 (en) | 1993-09-24 | 1994-09-26 | Method for the treatment or prevention of eczema/dermatitis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5798335A (https=) |
| EP (1) | EP0871466B1 (https=) |
| JP (1) | JP3623231B2 (https=) |
| AU (1) | AU697847B2 (https=) |
| CA (1) | CA2172491A1 (https=) |
| DE (1) | DE69433763T2 (https=) |
| DK (1) | DK0871466T3 (https=) |
| ES (1) | ES2218528T3 (https=) |
| WO (1) | WO1995008338A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025123114A1 (pt) * | 2023-12-15 | 2025-06-19 | Chemyunion Ltda | Composição cosmética, cosmecêutica e/ou farmacêutica, usos e métodos |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3895393A (en) * | 1992-03-27 | 1993-11-08 | Advanced Immunit, Inc. | Peptide T and related peptides in the treatment of inflammatory bowel disease |
| AU3871993A (en) * | 1992-06-15 | 1993-12-16 | Advanced Immunit, Inc. | Treatment of tropical spastic paresis with peptide t |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4689398A (en) * | 1984-06-20 | 1987-08-25 | Ortho Diagnostic Systems Inc. | HTLV test using synthetic peptides |
| US5189022A (en) * | 1988-05-27 | 1993-02-23 | The United States Of America As Represented By The Secretary Of Health And Human Services | Composition for the treatment of chronic fatigue syndrome |
| US5063206A (en) * | 1988-12-16 | 1991-11-05 | The United States Of Americas As Represented By The Department Of Health And Human Services | Compositions having use as treatment of neuropsychiatric deficits |
| WO1989012067A1 (en) * | 1988-05-27 | 1989-12-14 | The United States Of America, As Represented By Th | Compositions having use as treatment of psoriasis and neuropsychiatric deficits |
| DK31991D0 (da) * | 1991-02-25 | 1991-02-25 | Carlbiotech Ltd As | Peptid og farmaceutisk praeparat indeholdende et saadant peptid |
| US5651993A (en) * | 1992-11-18 | 1997-07-29 | Yale University | Specific immune system modulation |
-
1994
- 1994-09-26 DE DE69433763T patent/DE69433763T2/de not_active Expired - Fee Related
- 1994-09-26 DK DK94928213T patent/DK0871466T3/da active
- 1994-09-26 CA CA002172491A patent/CA2172491A1/en not_active Abandoned
- 1994-09-26 ES ES94928213T patent/ES2218528T3/es not_active Expired - Lifetime
- 1994-09-26 EP EP94928213A patent/EP0871466B1/en not_active Expired - Lifetime
- 1994-09-26 US US08/619,462 patent/US5798335A/en not_active Expired - Fee Related
- 1994-09-26 AU AU77350/94A patent/AU697847B2/en not_active Ceased
- 1994-09-26 WO PCT/AU1994/000574 patent/WO1995008338A1/en not_active Ceased
- 1994-09-26 JP JP50944495A patent/JP3623231B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3895393A (en) * | 1992-03-27 | 1993-11-08 | Advanced Immunit, Inc. | Peptide T and related peptides in the treatment of inflammatory bowel disease |
| AU3871993A (en) * | 1992-06-15 | 1993-12-16 | Advanced Immunit, Inc. | Treatment of tropical spastic paresis with peptide t |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0871466A1 (en) | 1998-10-21 |
| EP0871466B1 (en) | 2004-05-06 |
| DE69433763T2 (de) | 2005-04-14 |
| JP3623231B2 (ja) | 2005-02-23 |
| EP0871466A4 (https=) | 1998-11-11 |
| AU7735094A (en) | 1995-04-10 |
| WO1995008338A1 (en) | 1995-03-30 |
| ES2218528T3 (es) | 2004-11-16 |
| US5798335A (en) | 1998-08-25 |
| JPH09506860A (ja) | 1997-07-08 |
| CA2172491A1 (en) | 1995-03-30 |
| DE69433763D1 (de) | 2004-06-09 |
| DK0871466T3 (da) | 2004-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0139632B1 (ko) | 브라디키닌 길항 작용을 갖는 펩티드 | |
| JP2016516062A (ja) | 医薬組成物 | |
| CA2021948A1 (en) | Fibrinogen receptor antagonists | |
| CA2112907C (en) | Peptide which abrogates tnf and/or lps toxicity | |
| KR0173976B1 (ko) | 브라디키닌에 대하여 길항작용을 하는 펩타이드 | |
| US5627035A (en) | Peptides that block human immunodeficiency virus and methods of use thereof | |
| IL94939A (en) | Transformed Analogs of Maginin Peptide and Their Use | |
| JPS59196848A (ja) | アルギニンバソプレツシンの抗利尿作用の新規な「きっ」抗剤 | |
| ATE392428T1 (de) | Arzneimittel enthaltend analgetische peptide | |
| US4481194A (en) | Des-proline-des-glycine vasopressin antagonists | |
| AU697847B2 (en) | Method for the treatment or prevention of eczema/dermatitis | |
| EP0269299A2 (en) | Atrial peptides | |
| EP0635027B1 (en) | Peptide t and related peptides in the treatment of inflammation, including multiple sclerosis | |
| ATE33659T1 (de) | Basische hexa- und heptapeptide als vasopressin- antagonisten. | |
| US5795858A (en) | Treatment or prevention of Crohn's disease and/or ulcerative colitis | |
| AU667290B2 (en) | Peptides that block human immunodeficiency virus infections and methods of use thereof | |
| JPH0232098A (ja) | Ｄ―ｃｙｓ↑６バソプレシン拮抗剤 | |
| AU673332C (en) | Peptide which abrogates TNF and/or LPS toxicity | |
| WO2014075137A1 (en) | Peptides incorporating amino-substituted lactams for treatment of retinopathy | |
| WO1998013032A1 (en) | Compositions of therapeutic agents suitable for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Assignment registered |
Owner name: ON="ADVANCED" IMMUNI T, INC.; FT="FORMER" OWNER WAS: P |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |